Tides Express | Novo Nordisk Partners with GoodRx to Offer Semaglutide at $499 per Month

Aug 19, 2025 09:22 CST Updated 09:22

GoodRx

Prescription Drug Search and Price Comparison Platform

Novo Nordisk

Insulin Developer and Manufacturer

｜Edited by the Content Team of Zhong Peptide Biochemical

2025Year August18Day，Novo Nordisk announced that patients can now purchase semaglutide for $499 per month through its self-funded pharmacy platform, NovoCare, which is approximately half the marked price in the U.S. market. Additionally, Novo Nordisk has partnered with the drug discount platform GoodRx to leverage GoodRx’s channels and technology, enabling access to discounted semaglutide and Wegovy across the United States, also priced at $499 per month.The list price for the weight-loss drug Wegovy is $1,349, while Ozempic's is $998.

This collaboration comes at a time when demand for GLP-1 drugs is surging. GoodRx reported that in the past year, nearly 17 million people visited its platform seeking discounts and information on these drugs — a 22% increase year-over-year.

GoodRx President and CEO Wendy Barnes said, "Demand for GLP-1 drugs is at an all-time high, but too many Americans still face barriers to accessing these medications. By partnering with Novo Nordisk, we are taking a significant step in making these innovative brand-name treatments more accessible to the millions who need them."

This agreement addresses a significant gap in the market, as many patients lack insurance coverage for these medications, particularly when they are used for weight loss. Research from GoodRx shows that 19 million people have no insurance coverage for prescriptions of GLP-1 drugs used for weight management.

About Semaglutide

Semaglutide is a GLP-1 receptor agonist that stimulates insulin production, inhibits glucagon secretion, reduces appetite, and decreases food intake. Semaglutide was initially developed as a treatment for type 2 diabetes.ApprovedLaunched (Brand Name: Ozempic), in view of its significant effect on weight loss, the FDA in June 2021ApprovalIt is used to treat ordinary obese patients (trade name: Wegovy), which is the first new drug approved by the US FDA for controlling common obesity or overweight since 2014. The drug was subsequently approved by the EU for the treatment of obesity indications later in the same year.

About Novo Nordisk

Novo Nordisk, founded in 1923, is a global leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. Our goal is to drive change to defeat diabetes, obesity, rare blood diseases, endocrine disorders, and other serious chronic diseases. To achieve this goal, we lead scientific breakthroughs, expand the accessibility of our medicines, and are committed to preventing and ultimately curing diseases. Novo Nordisk has approximately 47,000 employees across 80 countries and regions worldwide, providing products and services to more than 168 countries and regions globally.

Source:

1.News Information